ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma

Toxicological Sciences

Volumn 124, Issue 1, 2011, Pages 75-87

  Cohen, Jennifer D ^a,d   Gard, Jaime M C ^b   Nagle, Raymond B ^b,c   Dietrich, Justin D ^a   Monks, Terrence J ^a   Lau, Serrine S ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

Author keywords

MAPK; Phosphorylation; Quinol thioether; Raf 1; Renal cell carcinoma

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; B RAF KINASE; B RAF KINASE INHIBITOR; CYCLIN D1; HYDROQUINONE; INITIATION FACTOR 4E BINDING PROTEIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; QUINOLINE; RAF PROTEIN; REGULATOR PROTEIN; SMALL INTERFERING RNA; SORAFENIB; SULFIDE; TUBERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL GROWTH; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY EPITHELIUM; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TUBEROUS SCLEROSIS; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CARCINOMA, RENAL CELL; CARRIER PROTEINS; CELL CULTURE TECHNIQUES; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; EPITHELIAL CELLS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; HYDROQUINONES; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MAP KINASE KINASE KINASES; PHOSPHOPROTEINS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS B-RAF; RATS; RATS, MUTANT STRAINS; RECEPTOR CROSS-TALK; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84155175868     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfr203     Document Type: Article

References (62)

1. Alao, J. P. (2007). The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol. Cancer 6, 24.
2. Balmanno, K., and Cook, S. J. (1999). Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 18, 3085-3097.
3. Beretta, L., Gingras, A. C., Svitkin, Y. V., Hall, M. N., and Sonenberg, N. (1996). Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits capdependent initiation of translation. EMBO J. 15, 658-664.
4. Beugnet, A., Wang, X., and Proud, C. G. (2003). Target of rapamycin (TOR)-signaling and RAIP motifs play distinct roles in the mammalian TORdependent phosphorylation of initiation factor 4E-binding protein 1. J. Biol. Chem. 278, 40717-40722.
5. Cantin, G. T., Yi, W., Lu, B., Park, S. K., Xu, T., Lee, J. D., and Yates, J. R., III. (2008). Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J. Proteome Res. 7, 1346-1351.
6. Castellvi, J., Garcia, A., Rojo, F., Ruiz-Marcellan, C., Gil, A., Baselga, J., and Ramon y Cajal, S. (2006). Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107, 1801-1811.
7. Cohen, J. D., Tham, K. Y., Mastrandrea, N. J., Gallegos, A. C., Monks, T. J., and Lau, S. S. (2011). cAMP-dependent cytosolic mislocalization of p27kipcyclin D1 during quinol-thioether induced tuberous sclerosis renal cell carcinoma. Toxicol. Sci. 122, 361-371.
8. Cook, S. J., Rubinfeld, B., Albert, I., and McCormick, F. (1993). RapV12 antagonizes ras-dependent activation of ERK1 and ERK2 by LPA and EGF in Rat-1 fibroblasts. EMBO J. 12, 3475-3485.
9. Coqueret, O. (2002). Linking cyclins to transcriptional control. Gene 299, 35-55.
10. Dephoure, N., Zhou, C., Villen, J., Beausoleil, S. A., Bakalarski, C. E., Elledge, S. J., and Gygi, S. P. (2008). A quantitative atlas of mitotic phosphorylation. Proc. Natl. Acad. Sci. U.S.A. 105, 10762-10767.
11. Eker, R., and Mossige, J. (1961). A dominant gene for renal adenomas in the rat. Nature 189, 858-859.
12. Everitt, J. I., Goldsworthy, T. L., Wolf, D. C., and Walker, C. L. (1992). Hereditary renal cell carcinoma in the Eker rat: a rodent familial cancer syndrome. J. Urol. 148, 1932-1936.
13. Garnett, M. J., Rana, S., Paterson, H., Barford, D., and Marais, R. (2005). Wildtype and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963-969.
14. Gevaert, K., Goethals, M., Martens, L., Van Damme, J., Staes, A., Thomas, G. R., and Vandekerckhove, J. (2003). Exploring proteomes and analyzing protein processing by mass spectrometric identification of sorted N-terminal peptides. Nat. Biotechnol. 21, 566-569.
15. Gingras, A. C., Gygi, S. P., Raught, B., Polakiewicz, R. D., Abraham, R. T., Hoekstra, M. F., Aebersold, R., and Sonenberg, N. (1999). Regulation of 4EBP1 phosphorylation: a novel two-step mechanism. Genes Dev. 13, 1422-1437.
16. Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K., Polakiewicz, R. D., Wyslouch-Cieszynska, A., Aebersold, R., and Sonenberg, N. (2001). Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 15, 2852-2864.
17. Haystead, T. A., Haystead, C. M., Hu, C., Lin, T. A., and Lawrence, J. C., Jr. (1994). Phosphorylation of PHAS-I by mitogen-activated protein (MAP) kinase. Identification of a site phosphorylated by MAP kinase in vitro and in response to insulin in rat adipocytes. J. Biol. Chem. 269, 23185-23191.
18. Hidalgo, M., and Rowinsky, E. K. (2000). The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686.
19. Hino, O., Kobayashi, E., Hirayama, Y., Kobayashi, T., Kubo, Y., Tsuchiya, H., Kikuchi, Y., and Mitani, H. (1995). Molecular genetic basis of renal carcinogenesis in the Eker rat model of tuberous sclerosis (Tsc2). Mol. Carcinog. 14, 23-27.
20. Hu, C. D., Kariya, K., Kotani, G., Shirouzu, M., Yokoyama, S., and Kataoka, T. (1997). Coassociation of Rap1A and Ha-Ras with Raf-1 N-terminal region interferes with ras-dependent activation of Raf-1. J. Biol. Chem. 272, 11702-11705.
21. Huang, J., and Manning, B. D. (2008). The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem. J. 412, 179-190.
22. Imami, K., Sugiyama, N., Kyono, Y., Tomita, M., and Ishihama, Y. (2008). Automated phosphoproteome analysis for cultured cancer cells by twodimensional nanoLC-MS using a calcined titania/C18 biphasic column. Anal. Sci. 24, 161-166.
23. Inoki, K., Li, Y., Xu, T., and Guan, K. L. (2003). Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17, 1829-1834.
24. Jiang, B. H., and Liu, L. Z. (2008). Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist. Updates 11, 63-76.
25. Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132.
26. Karbowniczek, M., Cash, T., Cheung, M., Robertson, G. P., Astrinidis, A., and Henske, E. P. (2004). Regulation of B-Raf kinase activity by tuberin and Rheb is mammalian target of rapamycin (mTOR)-independent. J. Biol. Chem. 279, 29930-29937.
27. Kobayashi, T., Hirayama, Y., Kobayashi, E., Kubo, Y., and Hino, O. (1995). A germline insertion in the tuberous sclerosis (Tsc2) gene gives rise to the Eker rat model of dominantly inherited cancer. Nat. Genet. 9, 70-74.
28. Kremer, C. L., Klein, R. R., Mendelson, J., Browne, W., Samadzedeh, L. K., Vanpatten, K., Highstrom, L., Pestano, G. A., and Nagle, R. B. (2006). Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 66, 1203-1212.
29. Krymskaya, V. P. (2003). Tumour suppressors hamartin and tuberin: intracellular signalling. Cell. Signal. 15, 729-739.
30. Lau, S. S., Hill, B. A., Highet, R. J., and Monks, T. J. (1988). Sequential oxidation and glutathione addition to 1,4-benzoquinone: correlation of toxicity with increased glutathione substitution. Mol. Pharmacol. 34, 829-836.
31. Lau, S. S., Monks, T. J., Everitt, J. I., Kleymenova, E., and Walker, C. L. (2001). Carcinogenicity of a nephrotoxic metabolite of the "nongenotoxic" carcinogen hydroquinone. Chem. Res. Toxicol. 14, 25-33.
32. Lavoie, J. N., L'Allemain, G., Brunet, A., Muller, R., and Pouyssegur, J. (1996). Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J. Biol. Chem. 271, 20608-20616.
33. Liu, Y., and Gray, N. S. (2006). Rational design of inhibitors that bind to inactive kinase conformations. Nat. Chem. Biol. 2, 358-364.
34. Long, X., Lin, Y., Ortiz-Vega, S., Yonezawa, K., and Avruch, J. (2005). Rheb binds and regulates the mTOR kinase. Curr. Biol. 15, 702-713.
35. Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., 3rd., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007). ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-1166.
36. Molina, H., Horn, D. M., Tang, N., Mathivanan, S., and Pandey, A. (2007). Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc. Natl. Acad. Sci. U.S.A. 104, 2199-2204.
37. Mulloy, R., Salinas, S., Philips, A., and Hipskind, R. A. (2003). Activation of cyclin D1 expression by the ERK5 cascade. Oncogene 22, 5387-5398.
38. Nelsen, C. J., Rickheim, D. G., Tucker, M. M., Hansen, L. K., and Albrecht, J. H. (2003). Evidence that cyclin D1 mediates both growth and proliferation downstream of TOR in hepatocytes. J. Biol. Chem. 278, 3656-3663.
39. Okada, R. D., Platt, M. A., and Fleishman, J. (1982). Chronic renal failure in patients with tuberous sclerosis. Association with renal cysts. Nephron 30, 85-88.
40. Osborne, J. P., Fryer, A., and Webb, D. (1991). Epidemiology of tuberous sclerosis. Ann. N. Y. Acad. Sci. 615, 125-127.
41. Page, K., Li, J., and Hershenson, M. B. (1999). Platelet-derived growth factor stimulation of mitogen-activated protein kinases and cyclin D1 promoter activity in cultured airway smooth-muscle cells. Role of ras. Am. J. Respir. Cell Mol. Biol. 20, 1294-1302.
42. Patel, S. K., Ma, N., Monks, T. J., and Lau, S. S. (2003). Changes in gene expression during chemical-induced nephrocarcinogenicity in the Eker rat. Mol. Carcinog. 38, 141-154.
43. Peters, M. M., Jones, T. W., Monks, T. J., and Lau, S. S. (1997). Cytotoxicity and cell-proliferation induced by the nephrocarcinogen hydroquinone and its nephrotoxic metabolite 2,3,5-(tris-glutathion-S-yl)hydroquinone. Carcinogenesis 18, 2393-2401.
44. Rojo, F., Najera, L., Lirola, J., Jimenez, J., Guzman, M., Sabadell, M. D., Baselga, J., and Ramon y Cajal, S. (2007). 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin. Cancer Res. 13, 81-89.
45. Shaw, R. J., and Cantley, L. C. (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424-430.
46. Soucek, T., Pusch, O., Wienecke, R., DeClue, J. E., and Hengstschlager, M. (1997). Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J. Biol. Chem. 272, 29301-29308.
47. Soucek, T., Yeung, R. S., and Hengstschläger, M. (1998). Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc. Natl. Acad. Sci. U.S.A. 95, 15653-15658.
48. Stillwell, T. J., Gomez, M. R., and Kelalis, P. P. (1987). Renal lesions in tuberous sclerosis. J. Urol. 138, 477-481.
49. Talarmin, H., Rescan, C., Cariou, S., Glaise, D., Zanninelli, G., Bilodeau, M., Loyer, P., Guguen-Guillouzo, C., and Baffet, G. (1999). The mitogenactivated protein kinase kinase/extracellular signal-regulated kinase cascade activation is a key signalling pathway involved in the regulation of G(1) phase progression in proliferating hepatocytes. Mol. Cell. Biol. 19, 6003-6011.
50. Tee, A. R., Manning, B. D., Roux, P. P., Cantley, L. C., and Blenis, J. (2003). Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr. Biol. 13, 1259-1268.
51. Villanueva, J., Yung, Y., Walker, J. L., and Assoian, R. K. (2007). ERK activity and G1 phase progression: identifying dispensable versus essential activities and primary versus secondary targets. Mol. Biol. Cell 18, 1457-1463.
52. Walker, C., Goldsworthy, T. L., Wolf, D. C., and Everitt, J. (1992). Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. Science 255, 1693-1695.
53. Watanabe, G., Howe, A., Lee, R. J., Albanese, C., Shu, I. W., Karnezis, A. N., Zon, L., Kyriakis, J., Rundell, K., and Pestell, R. G. (1996). Induction of cyclin D1 by simian virus 40 small tumor antigen. Proc. Natl. Acad. Sci. U.S.A. 93, 12861-12866.
54. Weber, J. D., Raben, D. M., Phillips, P. J., and Baldassare, J. J. (1997). Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem. J. 326(Pt 1), 61-68.
55. Wellbrock, C., Karasarides, M., and Marais, R. (2004). The RAF proteins take centre stage. Nat. Rev. Mol. Cell. Biol. 5, 875-885.
56. Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004). BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099-7109.
57. Yeung, R. S. (2003). Multiple roles of the tuberous sclerosis complex genes. Genes Chromosomes Cancer 38, 368-375.
58. Yeung, R. S., Buetow, K. H., Testa, J. R., and Knudson, A. G., Jr. (1993). Susceptibility to renal carcinoma in the Eker rat involves a tumor suppressor gene on chromosome 10. Proc. Natl. Acad. Sci. U.S.A. 90, 8038-8042.
59. Yeung, R. S., Xiao, G. H., Jin, F., Lee, W. C., Testa, J. R., and Knudson, A. G. (1994). Predisposition to renal carcinoma in the Eker rat is determined by germ-line mutation of the tuberous sclerosis 2 (TSC2) gene. Proc. Natl. Acad. Sci. U.S.A. 91, 11413-11416.
60. Yoon, H. S., Monks, T. J., Everitt, J. I., Walker, C. L., and Lau, S. S. (2002). Cell proliferation is insufficient, but loss of tuberin is necessary, for chemically induced nephrocarcinogenicity. Am. J. Physiol. Renal Physiol. 283, F262-F270.
61. Yoon, H. S., Monks, T. J., Walker, C. L., and Lau, S. S. (2001). Transformation of kidney epithelial cells by a quinol thioether via inactivation of the tuberous sclerosis-2 tumor suppressor gene. Mol. Carcinog. 31, 37-45.
62. Yoon, H. S., Ramachandiran, S., Chacko, M. A., Monks, T. J., and Lau, S. S. (2004). Tuberous sclerosis-2 tumor suppressor modulates ERK and B-Raf activity in transformed renal epithelial cells. Am. J. Physiol. Renal Physiol. 286, F417-F424.